Monday, 17 August 2026European Markets
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI Agent Rollout Outpaces Data Trust and Readiness
Enterprise adoption of agentic AI is accelerating fast — Siemens deepening its NVIDIA partnership for self-verifying agentic AI in chip design, Manulife expanding its Microsoft AI-governance partnership, and a wave of infrastructure launches (NVIDIA GPU-accelerated data processing, Dell exascale storage, new AI chip generations) — even as a new Google Cloud survey shows the underlying data foundation isn't ready: companies have AI access to only 45% of their data on average, data laggards see access fall to 30% or less, and only about half of organizations trust their AI agents' decisions. Meanwhile, insider selling at enterprise-AI bellwether C3.ai (CEO Thomas Siebel offloading $4.8M in shares) hints at investor caution layered under the adoption hype.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts report JPMorgan Chase & Co.'s revenue for the same fiscal period (FY 2025) with the same observation date (2025-12-31), but with different values: $182.447 billion vs. $185 billion. The ~1.4% difference ($2.553 billion) is too large to be explained by rounding alone and represents conflicting data for the identical time period.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,810
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,810 facts checked against source5,217 source documents archived
Work with this data → vianewsagency.com

BENEVOLENTAI Stock Was 9.3% Up Today

Loading stream...

(VIANEWS) - The Market ended the session with BENEVOLENTAI (BAI.AS) jumping 9.3% to €1.41 on Wednesday, following the last session's upward trend. AEX-Index rose 1.63% to €768.14, after three consecutive sessions in a row of gains, on what was an all-around positive trend trading session today.

BENEVOLENTAI's last close was €1.29, 82.8% below its 52-week high of €7.50.

About BENEVOLENTAI

BenevolentAI S.A. operates as a clinical-stage AI-enabled drug discovery and development company. Its BenevolentAI platform powers in-house drug pipeline of drug programs. The company's therapeutic areas, include atopic dermatitis, ulcerative colitis, amyotrophic lateral sclerosis, glioblastoma multiforme, inflammatory bowel disease, antiviral, oncology, parkinson's disease, nonalcoholic steatohepatitis, fibrosis, inflammation, chronic kidney disease, and idiopathic pulmonary fibrosis. It has a collaboration with AstraZeneca to enhance understanding of complex disease biology and identify new targets. The company was founded in 2013 and is headquartered in London, United Kingdom.

Earnings Per Share

As for profitability, BENEVOLENTAI has a trailing twelve months EPS of €-1.49.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -152.53%.

Volatility

BENEVOLENTAI's last week, last month's, and last quarter's current intraday variation average was a negative 1.77%, a negative 2.65%, and a positive 4.22%.

BENEVOLENTAI's highest amplitude of average volatility was 5.52% (last week), 3.91% (last month), and 4.22% (last quarter).

Volume

Today's last reported volume for BENEVOLENTAI is 1448 which is 34.82% above its average volume of 1074.

Moving Average

BENEVOLENTAI's worth is way below its 50-day moving average of €1.83 and way under its 200-day moving average of €3.07.

More news about BENEVOLENTAI (BAI.AS).